Research Article | Volume: 7, Issue: 9, September, 2017

Design, synthesis, molecular docking and cytotoxicity evaluation of some novel 5-arylidene-3-(substituted phenyl)-2-(p-tolylamino)-4-imidazolones

Ahmed I. Khodair Mostafa M. Elbadawi Mohammed T. Elsaady Khaled R. A. Abdellatif   

Open Access   

Published:  Sep 30, 2017

DOI: 10.7324/JAPS.2017.70908
Abstract

Novel 5-arylidene-3-(substituted phenyl)-2-(p-tolylamino)-3,5-dihydro-4H-imidazol-4-ones 9a-f were designed and synthesized based on a thioxoimidazolidinone derivative (I) that has been reported to have cytotoxicity with topo I inhibition. The synthesized compounds were evaluated in vitro for their cytotoxicity against prostate cancer (PC-3) and breast cancer (MCF-7) cell lines along with normal lung fibroblast cell line (WI-38). RegardingPC-3, compounds 9b-f showed potent selective cytotoxicity with IC50 range (28-68 nmol/ml). While for MCF-7, 9b, 9d-f possessed potent selective cytotoxicity with IC50 range (34-82 nmol/ml). Compound (9b) emerged as the most potent analogue against both PC-3 and MCF-7 cells, with IC50 = 28 and 34 nmol/ml, respectively. While, compound (9e) is the second most potent against both PC-3 and MCF-7 cells, with IC50 = 33 and 36 nmol/ml and also is the most selective one against both cancer cell lines with Selectivity index = 4.15 and 3.80, respectively. Moreover, the docking results of 9b, e against topo I (PDB: 1SC7) versus compound (I) and (VI) were consistent with the cytotoxicity results and revealed that they bound to topo I in a similar manner with docking scores = -28.018 and -28.1490 kcal/mol, respectively suggesting their use as lead compounds for developing topo I inhibitors.


Keyword:     4-imidazolones cytotoxicity prostate cancer breast cancer topoisomerase I.


Citation:

Khodair AI, Elbadawi MM, Elsaady MT, Abdellatif KRA. Design, synthesis, molecular docking and cytotoxicity evaluation of some novel 5-arylidene-3-(substituted phenyl)-2-(p-tolylamino)-4- imidazolones. J App Pharm Sci, 2017; 7 (09): 058-068.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Article Metrics
405 Views 26 Downloads 431 Total

Year

Month

Related Search

By author names